Acorda halts heart failure trial; AstraZeneca set to make brodalumab decision;

@FierceBiotech: ICYMI yesterday: Bristol-Myers fires off a lawsuit to sideline R&D defector headed to rival AstraZeneca. Article | Follow @FierceBiotech

@JohnCFierce: Top #ASCO15 story for @FierceBiotech: Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer. Story | Follow @JohnCFierce

@DamianFierce: Kinda feels like $JUNO Googled "CAR-T" and is gradually buying the whole first page of results. Release | Story | Follow @DamianFierce

> Acorda Therapeutics ($ACOR) has paused a Phase Ib trial on the heart failure treatment cimaglermin alfa after observing kidney damage in some patients. More

> AstraZeneca ($AZN) plans to decide in a "few weeks" whether to carry on with brodalumab, an investigational psoriasis treatment whose ties to suicidal thoughts led partner Amgen ($AMGN) to walk away from the project last month. News

> Novartis' ($NVS) anti-inflammatory treatment secukinumab succeeded in a Phase III study in ankylosing spondylitis, the company's next desired indication after winning approval in psoriasis. Story

Medical Device News

@FierceMedDev: ICYMI: Fierce exclusive: Zimmer to cut staff, close its dental headquarters following $13B merger with Biomet. Report | Follow @FierceMedDev

@VarunSaxena2: Hospitals tell feds that they can do more to support unique device ID. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Otsuka faces the music for generic Abilify, loses battle with  | Follow @EmilyWFierce

> Prenatal Dx player Natera looks to do an up to $100M IPO to expand, move into liquid biopsy. More

> Israeli startup unveils cloud-based mobile fetal monitor. Article

Pharma News

@FiercePharma: ICYMI: Look for orphan drugs to keep fueling M&A, Moody's says. Report | Follow @FiercePharma

@CarlyHFierce: Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA. More from FiercePharmaMarketing | Follow @CarlyHFierce

> Mylan deal target Perrigo bags GSK, Novartis consumer meds. News

> Mylan challenges Teva to put up a bid--or shut up and let it buy Perrigo. Report

Drug Delivery News

> NeuroVive's cardiology candidate fails to meet its endpoint. Item

> Cedars-Sinai team develops delivery-Dx combo nanomed for brain cancer. More

> Reassessment of trial data at ASCO to benefit Sirtex's cancer-fighting microspheres. Report

> Novartis partners with 'robotic' pillmaker in oral biologic race. Story

> FDA approves Lilly's reformulated insulin to foster patient convenience. Article

Pharma Manufacturing News

> Myanmar Pharma plans $30M upgrade to compete with Indian imports. Item

> South Korea's Green Cross building $240M plasma plant in Canada. More

> Hospira again shipping ketorolac but U.S. faces many drug shortages. Story

> Wockhardt looks to get banned plants back online in 2016. Article

> Sources: Cipla, Lupin bid on UCB's Kremers Urban. Report

Pharma Asia News

> Leading Japan drug firms team up with AZ on parasitic disease research. News

> SK Biopharmaceuticals says Jazz-led sleep disorder PhIII candidate on the cards. Report

> Taiwan recalls Y.F. Chemical sodium chloride products on new contamination events. Article

> Cipla, Lupin in UCB U.S. generics bid as India-linked M&A heats up. More

> Novartis India gets reprieve from NPPA on fine for over-pricing drug. Story

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.